Bio-Techne (TECH)
NASDAQ:TECH
Want to see TECH full AI Analyst Report?
TECH Stock Chart & Stats
$59.23
-$0.13(-0.17%)
At close: 4:00 PM EST
$59.23
-$0.13(-0.17%)
Day’s Range― - ―
52-Week Range$43.20 - $72.16
Previous CloseN/A
Volume102.39K
Average Volume (3M)3.34M
Market Cap
$8.77B
Enterprise Value$8.69B
Total Cash (Recent Filing)$209.82M
Total Debt (Recent Filing)$290.32M
Price to Earnings (P/E)78.3
Beta0.95
Next Earnings
Aug 11, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield0.54%
Share Statistics
EPS (TTM)0.71
Shares Outstanding156,568,760
10 Day Avg. Volume2,973,643
30 Day Avg. Volume3,336,483
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)4.22
Price to Sales (P/S)6.64
P/FCF Ratio31.59
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue7.18
Enterprise Value/Gross Profit11.05
Enterprise Value/Ebitda33.69
Forecast
1Y Price Target
$59.89Price Target Upside1.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)1.94
Revenue Forecast (FY)$1.21B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet & Low LeverageLow leverage and a strong equity base give Bio‑Techne durable financial flexibility through industry cycles. With modest debt (TTM D/E ~0.13) the company can fund product R&D, platform rollouts and geographic expansion without stressing liquidity, cushioning near-term revenue volatility and enabling strategic investments.
Robust Operating Cash Flow And Free Cash FlowHigh-quality cash generation (OCF covering operating profit and FCF tracking net income) provides a durable funding source for capex, strategic M&A, product development and shareholder returns. Strong TTM FCF growth (~+20.9%) supports reinvestment even if revenue recovery is gradual.
Spatial Biology / COMET Momentum And BacklogRapid COMET growth and a record backlog reflect structural demand for multiomic and spatial biology tools. Instrument placements drive recurring high-margin consumable sales and services, and early China installation signals scalable international adoption — a multi-quarter tailwind to revenue and margin if conversion persists.
Bears Say
Sharp TTM Revenue DeclineA ~39% TTM revenue drop materially reduces operating scale and dilutes fixed-cost leverage. Restoring pre-shock revenue levels will take multiple quarters and depends on external funding flows and order timing, limiting near-term organic growth visibility and constraining operational gearing benefits.
Compressed Net Margins And Operating ProfitabilitySustained margin compression from mix changes and volume deleverage weakens earnings power and free cash generation per dollar of revenue. Lower net margins reduce the firm's capacity to fund R&D, platform scaling, or buffer against future demand shocks, making recovery more reliant on restoring higher-margin sales.
Revenue Volatility Tied To Biotech Funding And Customer TimingDependence on large, lumpy orders and a biotech funding cycle with a 2–3 quarter lag creates structural revenue volatility. Timing effects from fast-track cell therapy customers and OEM shipments can swing quarters, complicating capacity planning, forecasting and consistent margin expansion until demand becomes more predictable.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $43.20 and its highest was $72.16 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $8.77B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is Aug 11, 2026 which is in 54 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on May 06, 2026. The company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.534 by -$0.004.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.54%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.52.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 156,568,760 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.53 in its last earnings report, missing expectations of $0.534. Following the earnings report the stock price went down -16.364%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Techne Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.89 (1.11% Upside)
$59.89 (1.11% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 327.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $320.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.17%
12-Months-Change
Fundamentals
Return on Equity
5.49%
Trailing 12-Months
Asset Growth
-3.54%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation, headquartered in Minneapolis, Minnesota, is a global enterprise specializing in the development, production, and distribution of specialized life science tools, instrumentation, and support solutions for both research and clinical diagnostic markets. The company is organized into two key business units: Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment manufactures a broad array of biological components, including cytokines, growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies, which are instrumental across life science research, diagnostic applications, and advancements in cell and gene therapy. This division further provides sophisticated proteomic analysis platforms, encompassing automated western blot and multiplexed ELISA workflows, coupled with relevant instrumentation and immunoassay kits designed for precise protein quantification in various biological fluids. The Diagnostics and Genomics segment is dedicated to developing and manufacturing diagnostic offerings, such as controls, calibrators, and specific diagnostic assays tailored for regulated markets. Its portfolio extends to innovative exosome-based molecular diagnostic tests, advanced in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and a variety of genetic and oncology kits for both research and clinical use. Additionally, this segment supplies products vital for genetic carrier screening, oncology diagnostics, molecular controls, and general research, alongside instrumentation and process controls for hematology, blood chemistry, gas analysis, and coagulation diagnostic applications. Its comprehensive product suite is offered under prominent brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen. Founded in 1976 as Techne Corporation, the company adopted its current name, Bio-Techne Corporation, in November 2014.
TECH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong execution in high-value growth vectors (Spatial Biology/COMET, GMP proteins excl. timing impacts, Proteomic Analysis instruments, large pharma strength and four consecutive quarters of China growth), solid sequential margin improvement and robust cash generation. Offsetting these positives were a 2% organic revenue decline, continued weakness in emerging/early-stage biotech spending, timing headwinds from two fast-track cell therapy customers and an OEM order, and YoY mix-related margin pressure. Management expects near-term organic revenue to be roughly flat but positions the business for an inflection in fiscal 2027 as funding improvements translate to customer spending.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
-0.08% Intersegment
0.34% Other revenue
TECH Stock 12 Month Forecast
Average Price Target
$59.89
▲(1.11% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.30% Insiders
41.71% Mutual Funds
21.62% Other Institutional Investors
9.54% Public Companies and
Individual Investors